CMS delayed a Medicare pilot intended to cover obesity medications after insurance plans indicated they would not participate at this time. The program, described in the report as tied to a broader attempt to expand access to obesity therapies within Medicare, hinges on insurer agreement and participation. The update reflects the mechanics of Medicare coverage pilots: even when federal policy seeks to adjust benefit constraints, participation from plans and operational willingness can determine whether the pilot moves forward. It also points to the financial and administrative risks insurers may associate with covering GLP-1 and similar weight-loss therapies. For the biotech and pharma community, the delay is a near-term access headwind that can affect demand forecasting, payer engagement strategies, and real-world treatment uptake. It also increases uncertainty around timelines for coverage expansion that drugmakers have been factoring into commercial planning.